← Back to patent-cliff list
GTAEXS-617
Tier C — Watch / tradeGTAEXS-617
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CDK7
Indications (approved)：Non-small cell lung cancer, 三阴性乳腺癌, Head and neck squamous cell carcinoma, Pancreatic cancer
Regional status
US
Phase II
2023-07-06
EU
Phase II
2023-07-06
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of GTAEXS-617?
Approved indications include: Non-small cell lung cancer, 三阴性乳腺癌, Head and neck squamous cell carcinoma, Pancreatic cancer.
When does the GTAEXS-617 patent expire?
No public expiry year is available for GTAEXS-617 yet; this page updates once verified.
How do I get a quote for GTAEXS-617 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02